MedTrace Logo

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-02-20

Study results available
· View outcomes & findings →

Summary

This study will test that hypothesis that topical administration of the FDA approved immunomodulatory agent cyclosporin A emulsion will minimize irritation and ocular surface disease that results from a short term low humidity environmental stress

Conditions

  • Dry Eye

Interventions

DRUG

Cyclosporin 0.05% emulsion

Topical therapy for dry eye

DRUG

Endura, Refresh artificial tears

Over the counter therapy for dry eye, used 4 times a day

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Stephen C. Pflugfelder, MD · Baylor College of Medicine, Department of Ophthalmology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02199964 on ClinicalTrials.gov